Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.47 |
| ▸ | AXL | P30530 | 2/20 | 0.35 |
| ▸ | MERTK | Q12866 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5749942 | 0.87 | KCNH2 (0.45) | KCNH2AXLMERTKCNR1CNR2 | |
| SCHEMBL5749909 | 0.86 | KCNH2 (0.57) | KCNH2AXLMERTKCNR1CNR2 | |
| SCHEMBL5749905 | 0.86 | KCNH2 (0.49) | KCNH2AXLMERTKCNR1CNR2 | |
| SCHEMBL5750027 | 0.85 | KCNH2 (0.48) | KCNH2AXLMERTKCNR1CNR2 | |
| SCHEMBL5750585 | 0.84 | KCNH2 (0.49) | KCNH2CNR1CNR2 | |
| SCHEMBL5750363 | 0.83 | KCNH2 (0.46) | KCNH2AXLMERTKCNR1CNR2 | |
| SCHEMBL5748528 | 0.81 | KCNH2 (0.47) | KCNH2CNR1CNR2 | |
| SCHEMBL5746005 | 0.76 | KCNH2 (0.45) | KCNH2 | |
| SCHEMBL5751526 | 0.74 | KCNH2 (0.42) | KCNH2 | |
| SCHEMBL14341308 | 0.74 | KCNH2 (0.51) | KCNH2CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1419155-B1 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2006-11-08 | — | — | EP | disclosed |
| US-20040198756-A1 | Medicaments | SMITHKLINE BEECHAM PLC (GB) | 2004-10-07 | — | — | US | disclosed |
| EP-1419155-A2 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003010138-A2 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198756-A1 | Medicaments | PIGO, PSAP, CD68 | KCNH2 3821/4885AXL 4679/4885MERTK 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.